As mentioned above, a recent clinical phase II study demonstrated that ibrutinib does not inhibit the growth and survival of BCR wild-type ABC-DLBCL tumors with MyD88 mutations [235, 239, 240]. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.